BB-102 (BroadenBio)

The main objectives are: 1) To evaluate the safety and tolerability of different doses of BB102 tablets alone (on an empty stomach or after a meal) in patients with advanced solid tumors; to observe the dose-limiting toxicity (DLT) of BB102 tablets alone (on an empty stomach or after a meal) within the prescribed dose range to explore the maximum tolerated dose (MTD) and provide a basis for determining the recommended dose (RP2D) for Phase II clinical trials; 3) To evaluate the efficacy of BB102 tablets alone (on an empty stomach) in patients with advanced primary HCC or other advanced solid tumors that are positive for FGF19 or FGFR4. Secondary objectives: 1) To investigate the pharmacokinetic (PK) characteristics of BB102 tablets (on an empty stomach) after single and multiple oral administration in patients with advanced solid tumors; 2) To preliminarily investigate the effect of food on the PK characteristics of BB102 tablets (on an empty stomach) after single and multiple oral administration in patients with advanced solid tumors; 3) To preliminarily investigate the efficacy of BB102 tablets (on an empty stomach or after meals) in patients with advanced solid tumors; 4) To investigate the relationship between biomarkers and efficacy and preliminarily infer the correlation; 5) To explore the correlation between blood drug concentration and Fridericia-corrected QT interval (QTcF) (C-QTcF analysis); 6) To identify the metabolites of BB102 in patients with advanced solid tumors; 7) To investigate the safety of BB102 tablets (on an empty stomach) in patients with advanced primary HCC or other advanced solid tumors that are positive for FGF19 or FGFR4.